Spots Global Cancer Trial Database for Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA

Official Title: Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA

Study ID: NCT03314051

Conditions

Nasopharyngeal Carcinoma

EBV Related Carcinoma

Interventions

Study Description

Brief Summary: No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.

Detailed Description: The stage III NPC patients were the majority group of the patient population of NPC. But most clinical trials focused on the treatment of American Joint Committee on Cancer (AJCC) 7th edition stage IVA/IVB treatment for high risk of recurrence or metastasis. No previous study reported the treatment outcome of stage III NPC patients. The investigators tried to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma EBV DNA assay for future therapy improvement.